New drug NAV-240 for hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This trial tests a new drug called NAV-240 for people with hidradenitis suppurativa (HS) who have not had success with antibiotics. The goal is to see if the drug can reduce the number of painful lumps and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hidradenitis suppurativa (HS) that has been stable for at least 2 months.
- You currently have at least 5 painful lumps (abscesses or inflamed nodules) on your skin.
- Your HS spots are in at least two different body areas, and at least one of those areas has moderate to severe disease (Hurley stage II or III).
- You have tried at least one course of antibiotics for your HS that didn't work well enough.
- You are not pregnant or planning to become pregnant, and if you are of childbearing age, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
This study tests a new injected medication (SPY072) for people with moderate to severe hidradenitis suppurativa (HS), a condition causing painful bumps and abscesses. The goal is to see if this treatment can reduce symptoms and improve quality of life.
This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.
This study tests a new medicine given by injection (anti-IL-17A/F antibody) combined with a laser treatment (non-ablative dot laser) for people with mild to moderate hidradenitis suppurativa (also called HS). The goal is to see if the combination is safe and works better than current options, and might help reduce pain and flare-ups.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.